Mutant Acetolactate Synthase Resists Valine Feedback
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing branched-chain L-amino acids, such as L-valine, are limited by feedback inhibition from valine, which restricts the productivity of these amino acids in bacterial fermentation processes.
Innovation Solution
A mutant bacterial acetolactate synthase (AHAS I) with specific mutations, including Asn-17 to Lys, Ala-30 to Pro, and Ile-44 to Arg and Phe, is developed to desensitize the enzyme to valine inhibition, enhancing the production of branched-chain L-amino acids by introducing these mutations into E. coli strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If wild-type acetolactate synthase is used in bacterial fermentation, then the enzyme maintains normal regulatory sensitivity to valine feedback inhibition, but the productivity of branched-chain L-amino acids is limited due to strong feedback inhibition
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of the acetolactate synthase enzyme at specific positions (Asn-17, Ala-30, Ile-44) to alter its regulatory properties. These mutations change the enzyme's sensitivity to valine feedback inhibition, transforming it from highly sensitive (wild-type) to resistant (mutant), thereby resolving the contradiction between maintaining regulatory sensitivity and improving productivity
Solution Approach 2:
The patent converts the harmful effect of feedback inhibition into a beneficial feature by creating a mutant enzyme that is resistant to valine inhibition. The mutations at positions 17, 30, and 44 transform the enzyme's response to valine from inhibitory to permissive, allowing continuous high-level production of branched-chain amino acids without the limiting feedback effect
2Productivity
If mutant acetolactate synthase with valine resistance is introduced, then the production of L-leucine, L-isoleucine, and L-valine is enhanced, but the enzyme loses normal feedback regulation control
Solution Approach 1:
The patent deliberately changes the regulatory parameter of the enzyme by introducing specific mutations (Asn-17, Ala-30, Ile-44) that alter the enzyme's response to valine. This parameter change transforms the feedback regulation from a limiting control mechanism to a permissive state, enabling enhanced productivity while accepting the trade-off of reduced regulatory control
Solution Approach 2:
The patent inverts the normal regulatory relationship by creating an enzyme that is resistant rather than sensitive to feedback inhibition. Instead of the wild-type enzyme being inhibited by valine (normal regulation), the mutant enzyme continues functioning despite valine presence, effectively inverting the regulatory response to achieve higher productivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The mutant acetolactate synthase increases the production of L-leucine, L-isoleucine, and L-valine by reducing feedback inhibition, leading to higher yields and improved fermentation efficiency.
Implementation Method 1
The AHAS reaction represents the first biosynthetic step common to the three products. The reaction is catalyzed by isoenzymes which are the target of end-product inhibition by valine. This regulation plays a major role in the physiological control of the pathway in bacteria.
Implementation Method 2
valine and its keto-acid precursor α-ketoisovaleric acid inhibit the growth of E. coli K12, and that isoleucine counters this inhibition. At present, it is commonly accepted that inhibition of valine primarily results from blocking α-aceto-α-hydroxybutyrate synthesis.
Data Source
AI summary
A mutant bacterial acetolactate synthase (AHAS I) which is resistant to feedback inhibition by L-valine is described. Also described is a method for producing branched-chain L-amino acids using a bacterium from the Enterobacteriaceae family wherein the L-amino acid productivity of said bacterium is enhanced by the use of the acetolactate synthase (AHAS I) which is resistant to feedback inhibition by L-valine. This acetolactate synthase contains a mutant small subunit encoded by the mutant ilvN gene.